CLINICAL TRIALS PROFILE FOR PF-06882961
✉ Email this page to a colleague
Clinical Trials for PF-06882961
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03309241 ↗ | First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects | Completed | Pfizer | Phase 1 | The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-06882961 in healthy adult subjects. This is the first clinical study of PF-06882961. |
| NCT03492697 ↗ | A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961 | Completed | Pfizer | Phase 1 | This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects. |
| NCT03538743 ↗ | 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes | Completed | Pfizer | Phase 1 | This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-06882961
Condition Name
Clinical Trial Locations for PF-06882961
Trials by Country
Clinical Trial Progress for PF-06882961
Clinical Trial Phase
Clinical Trial Sponsors for PF-06882961
Sponsor Name
